ABSTRACT
Objective To investigate the specific growth factor tumor (TSGF) in the treatment of chemoembolization (transcatheter) in the treatment of primary hepatic carcinoma (HCC) with the change of the level of arterial and transcatheter arterial chemoembolization (TACE),and the evaluation of the value in the treatment.Methods From January 2012 to December 2014 in Inner Mongolia Medical University affiliated Hospital,75 patients with primary liver cancer were treated by TACE,and all patients were treated with TACE.Then the changes of liver function,blood routine,alpha-fetoprotein (AFP),and TSGF levels were monitored at the preoperative,postoperative 1 week,1 month,and 3 months.The curative effect was evaluated.Results At 1 week after operation,aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were significantly higher than those before operation,but no differences were compared to the preoperative 1 month after operation.There was no significant difference in the level of WBC before and after operation.At 1 week after operation,the averaged AFP and TSGF water were significantly increased,but the 1 week after operation was significantly decreased.At 1 month after operation,there was no difference in the levels of TSGF and AFP between complete remission + partial remission + stable disease (CR + PR + SD) and progress disease (PD),and the levels of AFP and CR + PR + SD in PD patients were significantly lower than those in patients with TSGF at 3 months after operation.The levels of TSGF and AFP were lower in PD patients after 3 months,and there was no difference between TSGF and AFP levels at the different time after treatment in patients with CR + PR + SD.There was no significant difference in AFP levels before and after AFP treatment,and the average water level of TSGF before treatment was significantly higher than that of TACE before and after treatment.The difference was statistically significant (P ＜ 0.05).Conclusions TSGF level in patients with primary liver cancer patients with TACE treatment increased after the first rise,especially in the treatment of 1 month after the deterioration of the situation and the tumor has a significant correlation.In the evaluation of curative effect,it has a high value.Combined with AFP,CT examination can increase the long-term efficacy of TACE treatment of primary liver cancer.
ABSTRACT
Objective To evaluate the safety and effective of ultrasound-guide percutaneous radio frequency ablation (RFA).Methods Retrospectively analyze the incident,management and influence factors of complication of ultrasound-guide percutaneous RFA.Results From 2001 to 2011,536 patients with 762 lesions underwent RFA were enrolled in this study.Incident of RFA complication was 2.03％ (11/536),including 5 (0.92％) major complication.The complication covered fever (1 case),massive hydrothorax (2 cases),hydrothorax accompany with ascites (1 case),massive ascites (1 case),liver abscess (1 case),liver capsule hemorrhage (1 case) and hemothrorax (1 case).No RFA relate mortality was observed.According to logistics regression analysis,the liver function Child-Pugh grading was associated with the RFA complication (P =0.005).Conclusions Ultrasound-guide percutaneous RFA is a safe and effective local treatment approach for hepatocellular carcinoma.It's necessary to comprehensively think over the basic condition of patients and the characters of tumor such as tumor location,size and abutting organs.Nevertheless,an appropriate treatment plan and closely monitor during and after RFA are crucial.
ABSTRACT
Objective To evaluate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with three-dimension conformal radiotherapy (3DCRT) in treating unresectable primary Hepatic carcinoma(PHCC).Methods 64 cases of PHCC were randomly divided into 2 groups,TACE combined with 3DCRT group (Treatment group) and TACE alone group (control group).34 cases in treatment group were treated with TACE 2 ～3 times at first,after resting for 2-4 weeks,3DCRT treatment was used.30 cases in control group were treated with TACE 2 ～ 3 times only.Results The percentage of tumor regression rate (CR + PR) was 73.5% in treatment group and 36.6% in control group.The difference was significant (P ＜0.01).The percentage of AFP declined was 100% in treatment group and 92.9% in control group,which difference was not significant (P ＞0.05).The cumulative survival rate of 1-,2-and 3-years were 76.5%,58.8% and 41.2% in treatment group,and 56.7%,26.7%,13.3% in control group respectively.There was significant difference between the two groups (P ＜ 0.05).Conclusion The treatment of TACE combined with 3DCRT is an effective and security treatment method for primary Hepatic carcinoma.
ABSTRACT
Objective To study the changes in the immune function of advanced hepatic carcinoma patients after thermochemoembo-lization via hepatic artery. Methods Forty advanced hepatic carcinoma patients were randomized divided into 2 groups. A group (n=20) was treated by perfusion with ADM(40mg) + MMC(10mg) in 37℃ 9% sodium chloride solution via hepatic artery, and B group (n=20) was treated by perfusion with ADM(40mg) + MMC(10mg) in 60℃ 9% sodium chloride solution via hepatic artery, then all were embolized with some quantity of lipiodol. Flow cytometry (FCM) was used to detect the changes in percentages of T-lymphocyte subsets (CD3<'3, CD4<'+, CD8<'+) and NK cells, and the contents of soluble interleukin-2 receptor (sIL-2R) were detected by double sandwich ELISA before and after therapy. LDH enzyme-release assay was used to detect cytotoxic activity of NK cells. Results Compared with pre-therapy group or A group after therapy, the percentage of CD4<'+ cells of B group after therapy significantly increased (P<0.05), the percentages of CD8<'+ cells and the content of sIL-2R of B group after therapy markedly decreased (P<0.05). The percentages of NK cells and cytotoxic activity NK cells of B group after therapy were significantly higher than those from pre-therapy group or A group (P<0.05). Conclusion Intra-arterial thermochemoembolization may activate and improve cell-mediated immune function with a certain degree.